PX’Therapeutics and ADVAXIS to collaborate for the process development of lm based immunotherapies
[fusion_builder_container hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" enable_mobile="no" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" overlay_opacity="0.5" border_style="solid" padding_top="20px" padding_bottom="20px"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_3" spacing="" center_content="no" hover_type="none" link="" min_height="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" background_color="" background_image="" background_position="left top" background_repeat="no-repeat" border_size="0" border_color="" border_style="solid" border_position="all" padding="" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset="" last="no"][fusion_text] Grenoble (France), January 17th, 2018 PX’Therapeutics, a CDMO (Contract Development and Manufacturing [...]